X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TTK HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TTK HEALTHCARE DR. REDDYS LAB/
TTK HEALTHCARE
 
P/E (TTM) x 27.6 17.2 160.1% View Chart
P/BV x 3.4 5.6 60.7% View Chart
Dividend Yield % 0.8 0.5 149.4%  

Financials

 DR. REDDYS LAB   TTK HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
TTK HEALTHCARE
Mar-14
DR. REDDYS LAB/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,788663 420.3%   
Low Rs1,902399 476.6%   
Sales per share (Unadj.) Rs860.8535.6 160.7%  
Earnings per share (Unadj.) Rs57.115.9 357.9%  
Cash flow per share (Unadj.) Rs122.020.0 609.2%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.90.8 113.3%  
Book value per share (Unadj.) Rs757.7137.6 550.6%  
Shares outstanding (eoy) m165.917.77 2,135.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.0 274.7%   
Avg P/E ratio x41.133.3 123.3%  
P/CF ratio (eoy) x19.226.5 72.5%  
Price / Book Value ratio x3.13.9 80.2%  
Dividend payout %35.025.1 139.7%   
Avg Mkt Cap Rs m389,0344,127 9,425.6%   
No. of employees `00023.51.7 1,377.3%   
Total wages/salary Rs m32,149607 5,299.9%   
Avg. sales/employee Rs Th6,070.82,436.7 249.1%   
Avg. wages/employee Rs Th1,366.6355.2 384.8%   
Avg. net profit/employee Rs Th402.572.5 554.8%   
INCOME DATA
Net Sales Rs m142,8104,162 3,431.4%  
Other income Rs m1,55261 2,535.9%   
Total revenues Rs m144,3624,223 3,418.5%   
Gross profit Rs m23,512197 11,929.0%  
Depreciation Rs m10,77232 33,981.1%   
Interest Rs m78830 2,635.5%   
Profit before tax Rs m13,504197 6,865.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,38073 6,016.5%   
Profit after tax Rs m9,468124 7,641.6%  
Gross profit margin %16.54.7 347.6%  
Effective tax rate %32.437.0 87.6%   
Net profit margin %6.63.0 222.7%  
BALANCE SHEET DATA
Current assets Rs m104,9841,629 6,445.9%   
Current liabilities Rs m68,9381,058 6,517.1%   
Net working cap to sales %25.213.7 184.0%  
Current ratio x1.51.5 98.9%  
Inventory Days Days7430 249.7%  
Debtors Days Days10434 308.4%  
Net fixed assets Rs m104,385556 18,764.2%   
Share capital Rs m83078 1,068.2%   
"Free" reserves Rs m124,886878 14,219.1%   
Net worth Rs m125,7161,069 11,756.9%   
Long term debt Rs m25,089159 15,809.1%   
Total assets Rs m225,4432,399 9,395.8%  
Interest coverage x18.17.6 239.3%   
Debt to equity ratio x0.20.1 134.5%  
Sales to assets ratio x0.61.7 36.5%   
Return on assets %4.56.4 71.0%  
Return on equity %7.511.6 65.0%  
Return on capital %9.718.5 52.6%  
Exports to sales %00.8 0.0%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs mNA33 0.0%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m72,62333 220,738.6%   
Fx outflow Rs m18,91663 29,935.1%   
Net fx Rs m53,707-30 -177,309.3%   
CASH FLOW
From Operations Rs m18,030127 14,241.7%  
From Investments Rs m-14,883-146 10,193.8%  
From Financial Activity Rs m-4,44022 -20,274.0%  
Net Cashflow Rs m-1,2363 -49,440.0%  

Share Holding

Indian Promoters % 25.5 65.4 39.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 5.2 678.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.8 59.3%  
Shareholders   75,885 12,723 596.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

DR. REDDYS LAB Plunges by 5%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Dec 12, 2018 | Updated on Dec 12, 2018

DR. REDDYS LAB share price has plunged by 5% and its current market price is Rs 2,710. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 3.7%) and SUN PHARMA ADV. RES. (up 2.6%). The top losers is DR. REDDYS LAB (down 5.1%).

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Dec 12, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS